TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: - Subjects diagnosed with type 2 diabetes and on stable diabetes treatment with 1-2 OADs (Metformin equal to or above 1500 mg or maximum tolerated dose and/or thiazolidinedione (TZD) and sulfonylureas (SUs) equal to or above half of maximum dose allowed according to national label) for at least 90 days prior to screening. Stable is defined as unchanged medication and unchanged dose - HbA1c 7.0 - 10.5 % (53 - 91 mmol/mol) (both inclusive) Exclusion Criteria: - Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using an adequate contraceptive method throughout the trial including the 5 week follow-up period (adequate contraceptive measures as required by local law or practice) - Any chronic disorder or severe disease which, in the opinion of the investigator, might jeopardise subject's safety or compliance with the protocol - Treatment with glucose lowering agent(s) other than stated in the inclusion criteria in a period of 90 days before screening. An exception is short-term treatment (7 days or less in total) with insulin in connection with inter-current illness - History of chronic or idiopathic acute pancreatitis - Screening calcitonin value equal to or above 50 ng/L (pg/mL) - Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) - Impaired renal function defined as estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73 m\^2 per modification of diet in renal disease (MDRD) formula (4 variable version) - Acute coronary or cerebrovascular event within 90 days before randomisation - Heart failure, New York Heart Association (NYHA) class IV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide 1.0 mg (Type: EXPERIMENTAL): None
- Exenatide ER 2.0 mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is at least five years of age.~* Patient has been diagnosed with sickle cell anemia or sickle ß°-thalassemia (documented by hemoglobin electrophoresis).~* Patient has had at least two documented episodes of sickle cell crises within 12 months of the screening visit.~* If the patient has been treated with an anti-sickling agent within three months of the screening visit, the therapy must have been continuous for at least three months with the intent to continue for the duration of the study.~* Patient or the patient's legally authorized representative has given written informed consent.~* If the patient is a female of child-bearing potential, she agrees to avoid pregnancy during the study and is willing and agrees to practice a recognized form of birth control during the course of the study (e.g. barrier, birth control pills, abstinence).~Exclusion Criteria:~* Patient has a significant medical condition that required hospitalization (other than sickle cell crisis) within two months of the screening visit.~* Patient has prothrombin time INR \> 2.0.~* Patient has serum albumin \< 3.0 g/dl.~* Patient has received any blood products within three weeks of the Screening Visit.~* Patient has uncontrolled liver disease or renal insufficiency.~* Patient is pregnant or lactating or has the intention of becoming pregnant during the study (if female and of child-bearing potential).~* Patient is currently taking or has been treated with any form of glutamine supplement within 30 days of the screening visit.~* Patient has been treated with an experimental anti-sickling medication/ treatment within 30 days of the screening visit (with the exception of hydroxyurea in pediatric patients).~* Patient is currently taking or has been treated with an investigational drug within 30 days of the screening visit (with the exception of hydroxyurea in pediatric patients).~* Patient is currently enrolled in an investigational drug or device study and/or has participated in such a study within 30 days of the screening visit.~* There are factors that would, in the judgment of the investigator, make it difficult for the patient to comply with the requirements of the study.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- L-glutamine (Type: EXPERIMENTAL): Patients will be randomized to receive investigational product, L-Glutamine.
- 100% maltodextrin (Type: PLACEBO_COMPARATOR): Patients will be randomized to receive Placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male subjects 18 to \<65 years old with severe hemophilia A or B with or without inhibitors to FVIII or FIX.~* Subjects is willing and able to comply with the mandatory washout periods prior to screening and prior to dosing and through 48 hours post dosing. At screening this includes a washout of FIX for 96 hours and FVIII for 72 houts. At dosing this includes a washout of FIX for 96 hours and FVIII and other hemostatic agents for 72 hours through 48 hours post dosing.~* Subjects must agree and commit to using a a highly effective method of birth control from the time of screening through four weeks after study drug administration.~Exclusion Criteria:~* Presence of a bleeding disorder in addition to hemophilia A or B.~* Regular, concomitant therapy with immunomodulating drugs (eg, intravenous immunoglobulin, and routine systemic corticosteroids).~* History of coronary artery disease, thrombolic disease or diagnosis of prothrombic disorder.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None
- 4 (Type: EXPERIMENTAL): None
- 5 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age equal to or greater than 18 years, with chronic genotype 1b HCV infection;~* HCV RNA level \> 10,000 and \< 10,000,000 IU/ml at Screening;~* Rapid response to triple DAAs therapy with less than 500 IU/ml plasma HCV RNA level at Day 2;~* No evidence of cirrhosis. Cirrhosis defined as any 1 of the following, within 6 months of study entry:~  1. Liver biopsy showing cirrhosis;~ 2. Fibroscan showing cirrhosis or results\>12.5 kPa ;~ 3. FibroTest® score \>0.75 and an aspartate aminotransferase (AST): platelet ratio index (APRI) \>2 during screening.~Exclusion Criteria:~* Pregnant or nursing female or male with pregnant female partner;~* HIV or chronic hepatitis B virus (HBV) infection;~* Hematologic or biochemical parameters at Screening outside the protocol-specified requirements;~* Active or recent history (≤ 1 year) of drug or alcohol abuse;~* Hepatocellular carcinoma or other malignancy (with exception of certain resolved skin cancers);~* History or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study, or interfere with the subject's participation for the full duration of the study, such that it is not in the best interest of the subject to participate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDV/SOF+ASV (Type: EXPERIMENTAL): Participants with genotype 1b HCV infection will receive LDV/SOF FDC + ASV 3 weeks.
- SOF+DCV+SMV (Type: EXPERIMENTAL): Participants with genotype 1b HCV infection will receive SOF + DCV + SMV for 3 weeks.
- SOF+DCV+ASV (Type: EXPERIMENTAL): Participants with genotype 1b HCV infection will receive SOF + DCV + ASV for 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: House Dust Mite Treatment of Asthma. The MITRA Trial House Dust Mite Treatment of Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* A clinical relevant history consistent with house dust mite induced asthma of at least 1 year prior to trial entry.~* Use of an appropriate amount of inhaled corticosteroid for the control of asthma symptoms.~* Documented reversible airway obstruction.~* Suitable level of asthma control.~* FEV1 ≥ 70% of predicted value.~* Positive Skin Prick Test response to Der pte and/or Der far.~* Positive specific IgE against Der pte and/or Der far (≥ IgE Class 2; ≥ 0.70 KU/L).~Key Exclusion Criteria:~* A clinical history of persistent allergic asthma or rhinitis caused by an allergen to which the subject is regularly exposed and sensitised (except house dust mites).~* A clinical history of intermittent allergic asthma or rhinitis if the seasonal allergen is causing symptoms in the period from October to March.~* Any clinically relevant chronic disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- ALK HDM AIT 6 DU (Type: EXPERIMENTAL): None
- ALK HDM AIT 12 DU (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Placebo Versus Antibiotics in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Acute exacerbation of COPD type I or II according to GOLD~* Ability to perform lung function tests~* Ability to take oral medication~Exclusion Criteria:~* Pregnant or lactating women, or women of childbearing age not using an acceptable method of contraception.~* Pretreatment ( \> 24 hours) with an antibiotic for the present exacerbation.~* Pretreatment with corticosteroids (\>30 mg for more than 4 days) for the present exacerbation.~* Progression or new radiographic abnormalities on the chest X-ray.~* Severe exacerbation that required mechanical ventilation.~* History of bronchiectasis~* Recent or unresolved lung malignancy.~* Other disease likely to require antibiotic therapy.~* Significant gastrointestinal or other conditions that may affect study drug absorption.~* Class III or IV congestive heart failure or stroke.~* Immunodeficiency disorders such as AIDS, humoral immune defect, ciliary dysfunction etc. and the use of immunosuppressive drugs (\>30 mg prednisolone maintenance dose or equivalent for more than 4 weeks).~* Cystic fibrosis~* Tuberculosis.~* Impaired renal function (creatinine clearance \< 20 ml/min).

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: House Dust Mite SLIT in Elderly Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with allergic rhinitis who fulfilled the ARIA criterion and had a positive skin prick test (SPT), were positive for specific immunoglobulin E (sIgE) and had positive nasal provocation tests (NPTs) by Dermatophagoides pteronyssinus (Der p) and Dermatophagoides farinae (Der f) were included in the study~Exclusion Criteria:~* Patients with any of the following characteristics were excluded:~  * hypersensitivity to other allergens,~ * non-allergic rhinitis (especially senile or vasomotor rhinitis) or~ * severe non-stable diseases (especially bronchial asthma). However, stable coronary disease, diabetes, arterial hypertension and well-controlled, mild or atopic bronchial asthma were permitted.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- non immunotherapy treatment (Type: NO_INTERVENTION): None
- sublingual immunotherapy course (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with moderate to severe stable chronic obstructive pulmonary disease~* Smoking history of 10 pack years~* Post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) between 30 - 80%~* Patients must be able to use computer mouse and display~* mMRC grade\>2~Exclusion Criteria:~* Patients with a history of long QT syndrome~* Patients with Type I or uncontrolled Type II diabetes~* Patients who have had a COPD exacerbation or respiratory tract infection within 6 weeks prior to screening~* Patients with any history of asthma~* Patients with pulmonary lobectomy, lung volume reduction surgery, or lung transplantation~* Patients with concomitant pulmonary disease~* Patients requiring long term oxygen therapy (\>15 h a day)~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QVA149 + placebo to tiotropium (Type: EXPERIMENTAL): Participants received QVA149 plus placebo to tiotropium during 1 of 3 treatment periods, once a day for 6 weeks. Participants were provided with a salbutamol/albuterol inhaler to use as rescue medication.
- Tiotropium + placebo to QVA149 (Type: ACTIVE_COMPARATOR): Participants received tiotropium 18 μg plus placebo to QVA149 during 1 of 3 treatment periods once a day for 6 weeks. Participants were provided with a salbutamol/albuterol inhaler to use as rescue medication.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo to QVA149 plus placebo to tiotropium during 1 of 3 treatment periods once a day for 6 weeks. Participants were provided with a salbutamol/albuterol inhaler to use as rescue medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Recombinant Human Thrombin for Bleeding During Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is undergoing spinal surgery, hepatic resection, peripheral arterial bypass surgery, or arteriovenous graft formation for hemodialysis access~Exclusion Criteria:~* Subject has undergone a therapeutic surgical procedure within 30 days prior to surgery~* Subject has history of heparin-induced thrombocytopenia~* Subject has known antibodies or hypersensitivity to thrombin or other coagulation factors or known sensitivity to other components of the study treatment~* Subject has received blood products within 24 hours prior to surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): rThrombin
- 2 (Type: ACTIVE_COMPARATOR): bThrombin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Symptom Control Satisfaction With Proton Pump Inhibitor Regimen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years old~* taking omeprazole 20 mg~* episodic heartburn at least 3 times per week~* provides consent and be willing to complete study questionnaires~* read, speak and write English~Exclusion Criteria:~* weight loss (alarm symptom)~* normal esophagogastroduodenoscopy (EGD) in last one year~* pregnant or women planning on becoming pregnant at any time during the study~* history of Barrett's esophagus~* prior esophageal strictures~* intolerance/allergy to study medications~* patients on plavix or a history of upper gastrointestinal surgery~* investigators or their immediate family (spouse, children, sibling)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Sub-optimal dosing (Type: NO_INTERVENTION): No change will be made to the sub-optimal dosing regimen of omeprazole 20 mg. Rescue antacid use is permitted. Total duration of 6 weeks.
- Optimal dosing (Type: EXPERIMENTAL): Patients will be administered optimal dosing regimen of Omeprazole 20 mg for 4 weeks starting at week 2. Rescue antacid use is permitted. Total duration of 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Matricariae Chamomilla L., Melissa Officinalis L. and Tyndallized Lactobacillus Acidophilus (H122) for Infantile Colics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. diagnosis of IC according to Rome III criteria (2);~2. age ≥2 weeks to 4 months;~3. breast-fed or fomula-fed infants;~4. term delivery (≥37 weeks gestation at birth);~5. 5-minute Apgar score ≥7; and 6) birth weight ≥2500 g~Exclusion Criteria:~1. a major medical problem or acute illness;~2. family history of atopy;~3. history of antibiotic treatment before or during the study;~4. history of probiotic supplementation.

- Gender: ALL
- Minimum Age: 14 Days
- Maximum Age: 4 Months
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): All enrolled infants randomized to Group A will receive a standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized Lactobacillus Acidophilus (H122), administered at the dose of 1 ml twice a day of a commercially available solution
- Group B (Type: ACTIVE_COMPARATOR): All enrolled infants randomized to Group B will receive Lactobacillus reuteri DSM 17938 administered at the dose of 108 colony-forming units (CFU)/day in 5 drops of a commercially available oil suspension
- Group C (Type: ACTIVE_COMPARATOR): All enrolled infants randomized to Group C will receive simethicone, given at a dose of 60 mg in 15 drops two times per day of a commercially available solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* COPD patients having at least one exacerbation within last year~* FEV1/FVC ratio (post-bronchodilator) ≤ 70%~* FEV1 (post-bronchodilator) ≤ 50% of predicted~Main Exclusion Criteria:~* COPD exacerbation not resolved at first baseline visit~* Diagnosis of asthma and/or other relevant lung disease

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Roflumilast (Type: ACTIVE_COMPARATOR): 500 mcg, once daily, oral administration in the morning
- Placebo (Type: PLACEBO_COMPARATOR): once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete